HIM
URGN icon

Hillhouse Investment Management’s UroGen Pharma URGN Stock Holding History

Hillhouse Investment Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-352,300
Closed -$6.36M – 58
2017
Q2 		$6.36M Buy
+352,300
New +$6.12M 0.1% 44

Other funds holding URGN

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
DP
DSAM Partners London, United Kingdom $176M AUM 83.78% 1-Year Est. Return

Hillhouse Investment Management's URGN Position: Q3 2017 in Review

Hillhouse Investment Management sold out of UroGen Pharma (URGN) in Q3 2017, closing a stake of 352,300 shares — an estimated $6.36M sold.

Hillhouse Investment Management first reported a position in URGN in Q2 2017 and held it in 1 quarter. The position peaked at $6.36M in Q2 2017. 31 funds tracked by Wall St. Rank hold URGN as of Q3 2017.

  • Hillhouse Investment Management reported no remaining UroGen Pharma position as of Q3 2017 after selling out during the quarter.
  • Hillhouse Investment Management sold 352,300 UroGen Pharma shares in Q3 2017, an estimated $6.36M.
  • Hillhouse Investment Management first reported a position in UroGen Pharma in Q2 2017 and held it in 1 quarter.
  • Hillhouse Investment Management's UroGen Pharma position peaked at $6.36M in Q2 2017.
  • 31 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2017.

Based on Hillhouse Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.